1. Narimatsu H, Iwasaki H, Nakayama F, Ikehara Y, Kudo T, Nishihara S, Sugano K, Okura H, Fujita S, Hirohashi S. Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients. Cancer Res. 1998;58:512–8.
2. Dbouk M, Abe T, Koi C, Ando Y, Saba H, Abou Diwan E, Macgregor-Das A, Blackford AL, Mocci E, Beierl K, Dbouk A, He J, Burkhart R, Lennon AM, Sokoll L, Canto MI, Eshleman JR, Goggins M. Diagnostic performance of a tumor marker gene test to personalize serum CA19-9 reference ranges. Clin Cancer Res. 2023;11:23–0655.
3. Ando Y, Dbouk M, Blackford A, et al. Using a CA19-9 tumor marker gene test to assess outcome after pancreatic cancer surgery and response to neoadjuvant therapy. Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-024-14942-5.
4. Isaji S, Mizuno S, Windsor JA, Bassi C, Fernández-Del Castillo C, Hackert T, Hayasaki A, Katz MHG, Kim SW, Kishiwada M, Kitagawa H, Michalski CW, Wolfgang CL. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18:2–11.